glp-1 alternative for weight loss vs Ozempic — What's the Difference? FDA approves Foundayo, an oral

GLP-1RAs do not broadly cross the blood-brain barrier, but they can access neurons in the CVOs and in a few select sites in the hypothalamus [89]

[DOI] [PMC free article] [PubMed] [Google Scholar] 62.Coleman SK, Rebalka IA, DSouza DM, et al

Do not double dose to make up for a missed injection

Tirzepatide targets two, GLP-1 and GIP, which is why its called a dual agonist

Nature Malhotra A, et al

Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows